Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Minae An; Arnav Mehta; Byung‐Hoon Min; You Jeong Heo; Samuel J. Wright; Milan Parikh; Lynn Bi; Hyuk Lee; Tae Jun Kim; Song-Yi Lee; Jeonghyeon Moon; Ryan J. Park; Matthew R. Strickland; Woong‐Yang Park; Won Ki Kang; Kyoung‐Mee Kim; Seung Tae Kim; Samuel J. Klempner; Jeeyun Lee

doi:10.1158/2159-8290.25729035.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

(A) Swimmers plot of patient response and duration in the described clinical trial. (B) Scatter plot showing temporal course of tumor response measured by RECIST for all patients in the reported clinical trial. (C) Progression free survival (PFS) and (D) overall survival (OS) for all patients in the reported clinical trial separated by fast and slow progressors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

An et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4bab6db643587643a3f https://doi.org/10.1158/2159-8290.25729035.v1

View Full Paper

Ask AI

Bookmark

Share

Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Figure S1 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading